265 filings
Page 3 of 14
8-K
z5vcwpcq68b6so7h08je
11 Feb 19
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
5:25pm
8-K
idcu4zqwsvn5d
7 Feb 19
Other Events
4:30pm
8-K
z5gk1gn v7
18 Jan 19
Immunomedics Receives Complete Response Letter from Fda for Sacituzumab Govitecan Biologics License Application
12:00am
8-K
1gzftg
16 Jan 19
Other Events
12:00am
8-K
p2547a2djt02c16 dvyd
28 Dec 18
Entry into a Material Definitive Agreement
8:58am
8-K
pg5vxw r0dk7
26 Dec 18
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
8:30am
8-K
qq1jx7cexsn
17 Dec 18
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
1k5rlp o2
7 Nov 18
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
4:06pm
8-K
ukuosc6df2u
3 Oct 18
Entry into a Material Definitive Agreement
8:15am
8-K
xvjtjs 605fbj21
28 Sep 18
Departure of Directors or Certain Officers
4:30pm
8-K
mpw3 gm8a
12 Sep 18
Immunomedics and Samsung Biologics Announce Strategic Manufacturing Partnership
12:00am
8-K
nhxv97 sa43b7z0f45up
23 Aug 18
Departure of Directors or Certain Officers
12:00am
8-K
bqercgxma5hzlyp1s
23 Aug 18
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
12:00am
8-K
znlsglksnfnzj
18 Jul 18
Other Events
8:15am
8-K
l6nicr5 ix3
12 Jul 18
Entry into a Material Definitive Agreement
4:30pm
8-K
pflb05 swg6armbp
22 Jun 18
Other Events
4:33pm
8-K
g4m5l
15 Jun 18
Immunomedics Announces Proposed Public Offering of Common Stock
4:00pm
8-K
6vc9m2kohtmc0 qm
4 Jun 18
Immunomedics Announces Pivotal Study of Sacituzumab Govitecan In Patients with Locally Advanced or Metastatic Urothelial Cancer
12:00am
8-K
yhzwc4g2nz x8125q
4 Jun 18
Immunomedics Provides Business Update at the Asco 2018 Investor Event
12:00am
8-K
ps8yxj182wn mngvb
9 May 18
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
4:01pm